Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Needs A Deal On Drug Pricing As Shield Against Possible Democrat Wins – BIO’s Greenwood

Executive Summary

Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.

You may also be interested in...



Rebate Reporting Law May Provide Timely Trigger For US Pricing Debate – In 2023

Newly enacted requirement for US health plans to report granular drug price and rebating data to the government suggests that the great rebate debate of 2017-2020 won’t be over for long. The first public release of aggregated data will likely come in 2023 – and that might be when Congress is ready to take up drug pricing again.

Drug Pricing Reform In 2020 Gets Harder Due To Third Coronavirus Bill

Senate and House versions of a pending coronavirus stimulus package take off the table a key legislative vehicle lawmakers planned to use to push for bipartisan drug pricing reform until at least after the 2020 elections, signaling a potential reprieve for the pharmaceutical industry. 

MedPAC To The Rescue? How US Policy Advisors Could Save The Drug Industry

The Congressionally-chartered Medicare Payment Advisory Commission is preparing a formal endorsement of a plan to overhaul Part D. It will come just in time to help move stalled legislation – and that legislation may be the best chance the drug industry has to fend off draconian pricing measures in 2021.

Related Content

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel